Ultragenyx Pharmaceutical Inc. sank after the company’s experimental drug for a rare genetic bone disease failed to meet the primary endpoints in two phase 3 clinical trials.
Ultragenyx dropped 41% at 10 a.m. in New York Monday. Its shares had fallen 19% year to date through the close on Dec. 26.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.